Breaking barriers in breast cancer therapy

To honour Breast Cancer Awareness Month, we highlighted recent studies from the October issue focussing on overcoming therapy resistance in breast cancer. Wei et al. found that KH-3 could counter the oncogenic effects of HuR, a regulator of docetaxel resistance in triple-negative breast cancer (TNBC). Blasquez et al. showed the efficacy of ebselen oxide in repressing HER2, slowing down HER2-positive breast tumour progression.image

Automated summary

This article highlights recent studies on overcoming therapy resistance in breast cancer. It discusses the findings that KH-3 can counter the oncogenic effects of HuR, a regulator of docetaxel resistance in triple-negative breast cancer (TNBC), and that ebselen oxide shows efficacy in repressing HER2 and slowing down HER2-positive breast tumor progression.